Developer docs
API playgroundTry for free, no card

Search company profiles

Eurocine Vaccines

Full company profile

uuid0004ztk

Namestring
Eurocine Vaccines
Legal namestring
Eurocine Vaccines
Websiteurl
eurocine-vaccines.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Eurocine Vaccines is a privately held Swedish biotechnology company headquartered in Solna and founded in 1999. It develops nasal-delivery vaccines, with its primary focus on influenza vaccines formulated for children and the elderly, and it has also been referenced in third-party reporting as pursuing a Chlamydia vaccine with a 2026 milestone. The company operates with a very small team (1-10 employees) and has not disclosed commercial revenues, pricing, or named end customers in the available sources. A single capital event of approximately $29,325 was recorded in May 2023 with Merck listed as the investor; the small size of this event and absence of any larger financing rounds indicate the company remains at a pre-commercial, pipeline-development stage rather than a scaled commercial operation. (Note: the scraped content at the company's website URL is dominated by unrelated online-casino material, indicating domain or hosting contamination rather than actual company content, and should not be used to characterize the business.)

Short descriptiontext

Eurocine Vaccines is a small, privately held Swedish biotech developing nasal influenza vaccines for children and the elderly, with pipeline activity also referenced in Chlamydia vaccine development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
nasal flu vaccines, vaccine development, intranasal vaccines, pediatric vaccines, elderly vaccines
Industry3 codes
1Seasonal & Endemic Vaccines (e.g., Influenza)
CodeHLAIAEADPrimaryYes
2Prophylactic Human Vaccines (routine, pediatric, adult)
CodeHLAAAEAAPrimaryNo
3Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
CodeHLAAAEACPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eurocine Vaccines develops and produces nasal (intranasal) influenza vaccines primarily intended for children and the elderly. The company is a small biotech firm based in Solna, Sweden, founded in 1999, and also has a Chlamydia vaccine candidate referenced in its 2026 development pipeline alongside other pharmaceutical firms.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Nasal flu vaccine (children)
CategoryVaccines
Description

Intranasally administered influenza vaccine designed for children, offering a needle-free alternative to traditional injectable flu vaccines.

2Nasal flu vaccine (elderly)
CategoryVaccines
Description

Intranasally administered influenza vaccine designed for elderly users, providing a needle-free immunization option for a population that often has needle aversion or injection-site complications.

3Chlamydia vaccine candidate
CategoryVaccines
Description

Vaccine candidate for Chlamydia infections in the company's development pipeline (targeted for 2026), positioned alongside other pharmaceutical companies' chlamydia programs.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi's vaccines division is a global leader in influenza vaccines (Fluzone, Fluzone HD for elderly). Directly comparable as a competitor in seasonal and endemic flu vaccines for the same target populations.

2CSL Seqirus
TypeBroad incumbent
Description

One of the world's largest influenza vaccine manufacturers with established pediatric and adult flu franchises. Comparable as a broad incumbent in seasonal flu vaccines, the same indication Eurocine targets.

3GSK
TypeBroad incumbent
Description

Major vaccine manufacturer with established flu franchises (Fluarix, FluLaval) and a deep pediatric/geriatric vaccine portfolio. Comparable as a broad incumbent in seasonal influenza.

4Altimmune
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing intranasal vaccines, including a nasal influenza candidate (NasoVAX) using an adenovirus vector platform. Closest direct peer given shared intranasal delivery modality.

5FluGen
TypeEmerging player
Description

Clinical-stage company developing intranasal influenza vaccines (M2SR) targeting improved efficacy over standard IM flu shots. Comparable as a small-cap intranasal flu vaccine peer.

6Vaxart
TypeEmerging player
Description

Clinical-stage biotech developing oral pill vaccines including an oral influenza candidate. Comparable as an emerging needle-free vaccine delivery peer focused on improved compliance.

7Moderna
TypeBroad incumbent
Description

mRNA vaccine leader with seasonal influenza programs (mRNA-1010) targeting the same pediatric and elderly populations. Comparable as a broad incumbent pursuing next-generation flu vaccines.

8Novavax
TypeEmerging player
Description

Vaccine developer with recombinant nanoparticle flu vaccine candidates (NanoFlu) competing in the same seasonal influenza market. Comparable as an emerging alternative-vaccine-platform peer.

9Bharat Biotech
TypeRegional player
Description

India-based vaccine manufacturer with established nasal and intranasal vaccine capabilities (e.g., iNCOVACC intranasal COVID-19 vaccine). Comparable for nasal vaccine delivery expertise, though primarily serving Indian and emerging markets.

10Sinovac
TypeRegional player
Description

Chinese vaccine developer with seasonal influenza and pediatric vaccine products. Comparable as a regional vaccine manufacturer serving large pediatric flu populations, though geographically non-overlapping with Eurocine.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eurocine Vaccines

Vaccineseurocine-vaccines.com

Eurocine Vaccines is a small, privately held Swedish biotech developing nasal influenza vaccines for children and the elderly, with pipeline activity also referenced in Chlamydia vaccine development.

What Eurocine Vaccines does

Eurocine Vaccines is a privately held Swedish biotechnology company headquartered in Solna and founded in 1999. It develops nasal-delivery vaccines, with its primary focus on influenza vaccines formulated for children and the elderly, and it has also been referenced in third-party reporting as pursuing a Chlamydia vaccine with a 2026 milestone. The company operates with a very small team (1-10 employees) and has not disclosed commercial revenues, pricing, or named end customers in the available sources. A single capital event of approximately $29,325 was recorded in May 2023 with Merck listed as the investor; the small size of this event and absence of any larger financing rounds indicate the company remains at a pre-commercial, pipeline-development stage rather than a scaled commercial operation. (Note: the scraped content at the company's website URL is dominated by unrelated online-casino material, indicating domain or hosting contamination rather than actual company content, and should not be used to characterize the business.)

Eurocine Vaccines firmographics

Firmographics
Name
Eurocine Vaccines
Legal name
Eurocine Vaccines
Website
https://eurocine-vaccines.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1–10 employees
Short description
Eurocine Vaccines is a small, privately held Swedish biotech developing nasal influenza vaccines for children and the elderly, with pipeline activity also referenced in Chlamydia vaccine development.
Ownership category
akta.pro rank

Eurocine Vaccines industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)
akta.pro secondary industries
Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

  • Nasal flu vaccines
  • Vaccine development
  • Intranasal vaccines
  • Pediatric vaccines
  • Elderly vaccines

Where Eurocine Vaccines is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Markets served

Eurocine Vaccines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Eurocine Vaccines product offering

Product offering

Core offering

Eurocine Vaccines develops and produces nasal (intranasal) influenza vaccines primarily intended for children and the elderly. The company is a small biotech firm based in Solna, Sweden, founded in 1999, and also has a Chlamydia vaccine candidate referenced in its 2026 development pipeline alongside other pharmaceutical firms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nasal flu vaccine (children) Intranasally administered influenza vaccine designed for children, offering a needle-free alternative to traditional injectable flu vaccines.
  • Nasal flu vaccine (elderly) Intranasally administered influenza vaccine designed for elderly users, providing a needle-free immunization option for a population that often has needle aversion or injection-site complications.
  • Chlamydia vaccine candidate Vaccine candidate for Chlamydia infections in the company's development pipeline (targeted for 2026), positioned alongside other pharmaceutical companies' chlamydia programs.

Companies that use Eurocine Vaccines

Customer profile

Ideal customer profiles2 records

Eurocine Vaccines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Eurocine Vaccines partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Eurocine Vaccines competitors and assessment

Company assessment

Broad incumbents

  • Sanofi Pasteur: Sanofi's vaccines division is a global leader in influenza vaccines (Fluzone, Fluzone HD for elderly). Directly comparable as a competitor in seasonal and endemic flu vaccines for the same target populations.
  • CSL Seqirus: One of the world's largest influenza vaccine manufacturers with established pediatric and adult flu franchises. Comparable as a broad incumbent in seasonal flu vaccines, the same indication Eurocine targets.
  • GSK: Major vaccine manufacturer with established flu franchises (Fluarix, FluLaval) and a deep pediatric/geriatric vaccine portfolio. Comparable as a broad incumbent in seasonal influenza.
  • Moderna: mRNA vaccine leader with seasonal influenza programs (mRNA-1010) targeting the same pediatric and elderly populations. Comparable as a broad incumbent pursuing next-generation flu vaccines.

Emerging players

  • Altimmune: Clinical-stage biopharmaceutical company developing intranasal vaccines, including a nasal influenza candidate (NasoVAX) using an adenovirus vector platform. Closest direct peer given shared intranasal delivery modality.
  • FluGen: Clinical-stage company developing intranasal influenza vaccines (M2SR) targeting improved efficacy over standard IM flu shots. Comparable as a small-cap intranasal flu vaccine peer.
  • Vaxart: Clinical-stage biotech developing oral pill vaccines including an oral influenza candidate. Comparable as an emerging needle-free vaccine delivery peer focused on improved compliance.
  • Novavax: Vaccine developer with recombinant nanoparticle flu vaccine candidates (NanoFlu) competing in the same seasonal influenza market. Comparable as an emerging alternative-vaccine-platform peer.

Regional players

  • Bharat Biotech: India-based vaccine manufacturer with established nasal and intranasal vaccine capabilities (e.g., iNCOVACC intranasal COVID-19 vaccine). Comparable for nasal vaccine delivery expertise, though primarily serving Indian and emerging markets.
  • Sinovac: Chinese vaccine developer with seasonal influenza and pediatric vaccine products. Comparable as a regional vaccine manufacturer serving large pediatric flu populations, though geographically non-overlapping with Eurocine.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Eurocine Vaccines social profiles

Digital presence

Eurocine Vaccines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eurocine Vaccines leadership team

Management profile

Number of profiles

Profiles1 record

Eurocine Vaccines funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eurocine Vaccines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurocine Vaccines

What does Eurocine Vaccines do?

Eurocine Vaccines develops and produces nasal (intranasal) influenza vaccines primarily intended for children and the elderly. The company is a small biotech firm based in Solna, Sweden, founded in 1999, and also has a Chlamydia vaccine candidate referenced in its 2026 development pipeline alongside other pharmaceutical firms.

When was Eurocine Vaccines founded?

Eurocine Vaccines was founded in 1999. It employs 1 to 10 people.

Where is Eurocine Vaccines based?

Eurocine Vaccines is headquartered in Solna, Sweden, in the Europe region.

Who are Eurocine Vaccines's main competitors?

Broad incumbents on record are Sanofi Pasteur, CSL Seqirus, GSK and Moderna. Emerging players are Altimmune, FluGen, Vaxart and Novavax. Regional players are Bharat Biotech and Sinovac.

Does Eurocine Vaccines have an API?

No public API is recorded for Eurocine Vaccines.

What industry is Eurocine Vaccines in?

Eurocine Vaccines's product category is Vaccines. Its primary akta.pro industry code is HLAIAEAD, Seasonal & Endemic Vaccines (e.g., Influenza), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOutstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidateEurocine Vaccines announced initial preclinical trial results for its mRNA-based therapeutic HSV-2 vaccine candidate, showing that the mRNA vaccine generated superior T cell responses compared to the protein vaccine version. The mRNA vaccine demonstrated particularly strong CD8 T cell responses, reaching up to 14% of total CD8 T cells in mouse spleens, and both vaccine platforms were well tolerated. The company plans to advance testing to guinea pigs with established HSV-2 infection in spring 2023, which will inform the final technology selection for the portfolio candidate.PR NewswireOutstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidateEurocine Vaccines announced positive preclinical results for its mRNA-based therapeutic HSV-2 vaccine candidate, demonstrating that the mRNA vaccine generated superior T cell responses compared to the protein vaccine in mouse studies. The mRNA vaccine elicited higher numbers of IFN-γ, IL-2, and TNF-α secreting T-cells, with CD8 responses reaching up to 14% of total CD8 T cells in the spleen. The company plans to advance to guinea pig studies in spring 2023, which will inform the final technology platform decision for the HSV-2 vaccine portfolio candidate.PR NewswirePositive results with Endocine™ and a vaccine candidate against COVID-19Eurocine Vaccines AB announced positive preclinical results from a study combining its adjuvant technology Endocine™ with a COVID-19 vaccine candidate developed by a North American partner company, with the mouse model study detecting both IgA and IgG antibodies as well as T cell immunity. The North American company has signed an evaluation agreement with Eurocine Vaccines in May 2021 and now plans to proceed with additional studies, with Eurocine Vaccines set to supply Endocine™ and provide scientific support.PR NewswireEurocine Vaccines extends its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia BiotechnologyEurocine Vaccines has widened its license agreement with Spixia Biotechnology to include a diagnostic test for chlamydia, leveraging the same active protein used in its vaccine development. The company plans to conduct initial experiments to evaluate the diagnostic test's design and functionality, with trials expected to conclude by the second quarter of 2022.PR NewswireEurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19Eurocine Vaccines has entered into a Material Transfer Agreement with an unnamed North American small public company to evaluate its Endocine™ adjuvant technology alongside a COVID-19 vaccine candidate. The collaboration involves animal studies to assess potency and safety, leveraging Endocine's established GMP manufacturing and prior clinical safety data.PR NewswireEurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidateEurocine Vaccines AB has selected Biovian Oy, a contract developer and manufacturer based in Turku, Finland, to develop an industrial manufacturing method and manufacture study products for the Company's chlamydia vaccine candidate. The collaboration will begin in January 2021 under an agreement signed December 30, 2020, with activities totaling approximately SEK 9.5 million (EUR 0.94 million) and initially lasting until November 2021. Biovian brings its own GMP facility to support Eurocine Vaccines' toxicological and clinical studies.PR NewswireEurocine Vaccines has Completed Dosing of its Quadrivalent Influenza Vaccine Candidate, Immunose™ FLU, in the Second Clinical StudyEurocine Vaccines has completed dosing in its second clinical study for Immunose™ FLU, a quadrivalent nasal influenza vaccine candidate, with results expected in the second half of 2018. The company chose the quadrivalent formulation over trivalent to provide broader protection against influenza strains. The vaccine is being developed to target both the elderly population, who are most vulnerable to influenza disease, and children under 2 years of age.PR NewswireEurocine Vaccines daagt de griep uitEurocine Vaccines has received two patents in Australia and the United States for its nasal flu vaccine technology, supported by positive results from recent clinical trials, positioning the company to advance toward approval for children under two years old. The company plans its next clinical study during the 2017/2018 flu season and will include elderly participants to study adjuvant effects in weaker immune systems while expanding into a new market segment. Eurocine Vaccines continues to evaluate broadening its nasal vaccine product portfolio both independently and with partners, leveraging its Endocine™ technology platform.PR NewswireEurocine Vaccines relève le défi de la grippeEurocine Vaccines announced it is preparing for a second clinical study of its nasal flu vaccine candidate Immunose™ FLU, following positive results from an earlier study and the recent granting of patents in Australia and the United States. The company, which aims to develop the first nasal flu vaccine approved for children under two years old, has expanded its next trial to include elderly populations, a strategic choice to enrich data on adjuvant effects in weaker immune systems and open an additional market segment. The company plans to continue evaluating portfolio expansion of its Endocine™ nasal vaccination technology both independently and with partners.PR NewswireEurocine Vaccines Challenges the FluEurocine Vaccines is advancing its nasal influenza vaccine candidate Immunose™ FLU to a second clinical study, building on positive results from an initial trial and newly granted patents in Australia and the USA. The next study will include elderly subjects during the 2017/2018 influenza season, expanding into an additional market segment while maintaining focus on the company's goal of creating the first nasal influenza vaccine approved for children under two. The company uses its clinically validated Endocine™ technology platform to develop patent-protected nasal vaccines targeting children and the elderly, with children identified as the fastest-growing segment in the influenza vaccine market.